Fundraising Fox
Averetx
1 known investors
Find your way into Averetx
Sign up to see every warm intro you have to Averetx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Averetx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avere Therapeutics is a biotech company developing AVR-001, an oral once-weekly interleukin-23 receptor antagonist (IL-23RA) for chronic inflammatory diseases such as psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The drug is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly pill dosing.
Investors · 1
Frequently asked questions
- What does Averetx do?
- Avere Therapeutics is a biotech company developing AVR-001, an oral once-weekly interleukin-23 receptor antagonist (IL-23RA) for chronic inflammatory diseases such as psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The drug is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly pill dosing.
- Who are Averetx's investors?
- Averetx's investors include Wellington Management.